Baidu
map

J Clin Endocrinol Metab:肾移植患者不用强化血糖控制

2013-01-16 J Clin Endocrinol Metab CMT Alexa 译

  美国新泽西州的Hermayer KL博士今日发表在《临床内分泌杂志》上的研究表明:不建议肾移植患者术后进行强化血糖控制治疗。   研究人员对接受肾移植的患者进行了一项随机对照试验,将104例患者随机分配到强化组或对照组,强化组接受静脉胰岛素治疗IV(强化)治疗,对照组接受标准皮下胰岛素注射SC治疗。强化组肾移植后3天接受强化IV胰岛素治疗【血糖(BG)为70~110mg/dl】,对

  美国新泽西州的Hermayer KL博士今日发表在《临床内分泌杂志》上的研究表明:不建议肾移植患者术后进行强化血糖控制治疗。

  研究人员对接受肾移植的患者进行了一项随机对照试验,将104例患者随机分配到强化组或对照组,强化组接受静脉胰岛素治疗IV(强化)治疗,对照组接受标准皮下胰岛素注射SC治疗。强化组肾移植后3天接受强化IV胰岛素治疗【血糖(BG)为70~110mg/dl】,对照组接受SC胰岛素治疗(BG =70~180mg/dl)。主要观察指标的主要终点为移植物功能延迟恢复(DGF),次要终点为血糖控制、移植物存活和急性排斥反应。严重低血糖(BG=350mg/dl)的发生率是主要安全性结果指标。

  研究结果显示,104例患者中,有93例接受了肾移植:强化组44例,对照组49例。 强化治疗组中8例表现出DGF,对照组为12例。研究共出现9例低血糖,其中强化治疗组7例,对照组2例。此外,强化治疗组有5例患者发生30次高血糖,对照组有12例患者至少有一次高血糖。共发生11例排异反应,强化治疗组9例,对照组2例。

  两个治疗组中,主要终点DGF无统计学差异。考虑血糖水平、排斥反应和移植物存活,强化治疗组患者的排斥反应风险较高。 


A Randomized Controlled Trial to Evaluate the Effect of Glycemic Control on Renal Transplantation Outcomes

Context: Outcomes from intensive glycemic control postrenal transplant have not been studied.

Objective: Our objective was to observe the optimal management of hyperglycemia in patients with diabetes or impaired glucose tolerance receiving renal transplantation.

Design, Setting, and Patients: We conducted a randomized controlled trial with patients undergoing renal transplantation randomized to either iv insulin therapy (intensive) or standard sc insulin therapy while the patients were admitted to the hospital.

Interventions: The study consisted of a 3-day postrenal transplant group treated with intensive iv insulin [blood glucose (BG) = 70–110 mg/dl] or a control group treated with sc insulin (BG = 70–180 mg/dl).

Main Outcome Measure: The primary endpoint was delayed graft function (DGF). Secondary endpoints were glycemic control, graft survival, and acute rejection episodes.

Results: A total of 104 patients were screened and randomized to either the intensive or control condition; however, the intention-to-treat analysis set consisted of only the 93 participants (n = 44 intensive, n = 49 control) that underwent a renal transplant. DGF was present in 18% (eight of 44) of the intensive group and 24% (12 of 49) of the control group (P = 0.46). The occurrence of severe hypoglycemia (BG < 40 mg/dl) and severe hyperglycemia (BG > 350 mg/dl) were the primary safety outcome measures. There were nine participants with hypoglycemia identified, seven of which (78%) were in the intensive treatment group (P = 0.08). There were 30 instances of hyperglycemia with five participants (11%) in the intensive group and 12 participants (24%) in the control group having at least one hyperglycemic event (P = 0.10). For the 11 rejection episodes, nine were in the intensive treatment group (P = 0.013).

Conclusions: The primary outcome measure of DGF was not statistically different for the two treatment groups. Regarding longer-term rejection and graft survival, the intensively treated participants were at higher risk for a rejection episode.



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=23986, encodeId=bdb723986e7, content=能否扩展到一般术后管理, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9da1623000, createdName=darkdaisy, createdTime=Mon May 18 00:34:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887337, encodeId=c585188e337d9, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Sep 05 12:04:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895653, encodeId=f1371895653d9, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Aug 18 12:04:00 CST 2013, time=2013-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041967, encodeId=caa3204196e7f, content=<a href='/topic/show?id=85055014226' target=_blank style='color:#2F92EE;'>#强化血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50142, encryptionId=85055014226, topicName=强化血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu May 09 04:04:00 CST 2013, time=2013-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272889, encodeId=313812e28894f, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Fri Jan 18 07:04:00 CST 2013, time=2013-01-18, status=1, ipAttribution=)]
    2015-05-18 darkdaisy

    能否扩展到一般术后管理

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=23986, encodeId=bdb723986e7, content=能否扩展到一般术后管理, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9da1623000, createdName=darkdaisy, createdTime=Mon May 18 00:34:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887337, encodeId=c585188e337d9, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Sep 05 12:04:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895653, encodeId=f1371895653d9, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Aug 18 12:04:00 CST 2013, time=2013-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041967, encodeId=caa3204196e7f, content=<a href='/topic/show?id=85055014226' target=_blank style='color:#2F92EE;'>#强化血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50142, encryptionId=85055014226, topicName=强化血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu May 09 04:04:00 CST 2013, time=2013-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272889, encodeId=313812e28894f, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Fri Jan 18 07:04:00 CST 2013, time=2013-01-18, status=1, ipAttribution=)]
    2013-09-05 guojianrong
  3. [GetPortalCommentsPageByObjectIdResponse(id=23986, encodeId=bdb723986e7, content=能否扩展到一般术后管理, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9da1623000, createdName=darkdaisy, createdTime=Mon May 18 00:34:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887337, encodeId=c585188e337d9, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Sep 05 12:04:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895653, encodeId=f1371895653d9, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Aug 18 12:04:00 CST 2013, time=2013-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041967, encodeId=caa3204196e7f, content=<a href='/topic/show?id=85055014226' target=_blank style='color:#2F92EE;'>#强化血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50142, encryptionId=85055014226, topicName=强化血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu May 09 04:04:00 CST 2013, time=2013-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272889, encodeId=313812e28894f, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Fri Jan 18 07:04:00 CST 2013, time=2013-01-18, status=1, ipAttribution=)]
    2013-08-18 一闲
  4. [GetPortalCommentsPageByObjectIdResponse(id=23986, encodeId=bdb723986e7, content=能否扩展到一般术后管理, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9da1623000, createdName=darkdaisy, createdTime=Mon May 18 00:34:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887337, encodeId=c585188e337d9, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Sep 05 12:04:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895653, encodeId=f1371895653d9, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Aug 18 12:04:00 CST 2013, time=2013-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041967, encodeId=caa3204196e7f, content=<a href='/topic/show?id=85055014226' target=_blank style='color:#2F92EE;'>#强化血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50142, encryptionId=85055014226, topicName=强化血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu May 09 04:04:00 CST 2013, time=2013-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272889, encodeId=313812e28894f, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Fri Jan 18 07:04:00 CST 2013, time=2013-01-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=23986, encodeId=bdb723986e7, content=能否扩展到一般术后管理, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9da1623000, createdName=darkdaisy, createdTime=Mon May 18 00:34:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887337, encodeId=c585188e337d9, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Sep 05 12:04:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895653, encodeId=f1371895653d9, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Aug 18 12:04:00 CST 2013, time=2013-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041967, encodeId=caa3204196e7f, content=<a href='/topic/show?id=85055014226' target=_blank style='color:#2F92EE;'>#强化血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50142, encryptionId=85055014226, topicName=强化血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu May 09 04:04:00 CST 2013, time=2013-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272889, encodeId=313812e28894f, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Fri Jan 18 07:04:00 CST 2013, time=2013-01-18, status=1, ipAttribution=)]

相关资讯

CSN:防治甲状旁腺功能亢进或改善肾移植预后

    2012年4月25-29日,加拿大肾脏病学会(CSN)年会上,加拿大不列颠哥伦比亚大学圣保罗医院的Howard Yan医生报告的一项研究表明,高钙血症是肾移植后常见并发症,可利用移植前临床和实验室数据进行预测;骨矿物质代谢紊乱与同种异体肾移植失败风险升高有关;预防和治疗高钙血症可能是改善肾移植预后的重要策略,有必要进行进一步研究。     研究者回顾了20

AJKD:活体供肾者发生骨折的危险性

  CKD疾病会增加患者发生骨折的几率,捐肾者失去了正常50%的肾脏体积,其钙离子平衡会出现改变。   研究者对加拿大安大略1992-2009年一共2015名成人捐肾者资料进行回顾分析,同时从正常健康人群中选取20150名作为对照组,平均年龄在43岁,平均随访时间为6.6年,最长17.7年。统计结果显示捐肾者发生骨折的几率并没有高于对照组,多因素加入的分析结果也是未见显著差异;而年龄稍高的成年人接

JASN:供体特异性抗体对肾移植结果有负面影响

     目前关于敏感固相试验(SPAs)检测到的低定量供体特异性抗体(DSAs)对肾移植结果的影响仍然不清楚。来自哥伦比亚大学的研究者进行系统回顾和meta分析后发现,移植排异患者SPA显现出了阳性结果,而补体依赖性细胞毒和流式细胞术试验却是阴性结果。   研究者运用了7个回顾性队列研究,包括1119名患者,其中145位具有独立的DSA-SPA。尽管流式细胞术试验

肾移植与腹膜透析患者总体生活质量无显著差异

    最近, 北京大学护理学院内外科护理学教研室、北京大学护理学院的研究人员的一项研究显示,肾移植与腹膜透析患者总体生活质量无差异,仅个别维度有差异;良好的疾病管理能改善患者生活质量,应加强肾替代治疗患者的管理。 该研究发表于2012年第2期《中国血液净化》。     该研究旨在比较肾移植患者与腹膜透析患者的生活质量。     金三丽等研究人员采用

肾移植受者H1N1A型流感疫苗佐剂(Pandemrix®)的免疫反应

    60例患者和22名健康对照者参加了这一项前瞻性观察性研究,他们接受了单一计量的Pandemrix®注射。 接种疫苗前和后,测定H1N1抗体滴度以及抗HLA抗体滴度。 有19例患者接受了加强疫苗针,我们对所有肾移植受者(N = 107)的情况进行了观察。         结果显示:接种疫苗前,60例患者中有2例A型

Transplantation :尿液细胞mRNA检测有助预测和诊断移植肾纤维化

  肾小管间质纤维化是移植肾功能丢失的重要病理学特征,这需要通过侵袭性的肾脏病理活检才能确诊。如果能找到非侵袭性检查手段达到预测和早期诊断移植肾纤维化,将有效改善肾移植患者的预后。     法国学者Dany Anglicheau的团队的最新研究显示,检测尿液细胞mRNA有助早期诊断移植肾纤维化。研究者收集了114名肾移植受者的尿液标本,其中48名为肾活检确诊的移植肾纤维化患者,66名

Baidu
map
Baidu
map
Baidu
map